##### ยง 10.3 Definitions. #####

*Ceiling price* means the maximum statutory price established under section 340B(a)(1) of the PHSA.

*Covered entity* means an entity that meets the requirements under section 340B(a)(5) of the PHSA and is listed in section 340B(a)(4) of the PHSA.

*Covered outpatient drug* has the meaning set forth in section 1927(k) of the SSA.

*Group purchasing organization* (GPO) is an entity that contracts with purchasers, such as hospitals, nursing homes, and home health agencies, to aggregate purchasing volume and negotiate final prices with manufacturers, distributors, and other vendors.

*Manufacturer* has the same meaning as set forth in section 1927(k)(5) of the SSA.

*Orphan drug* means a drug designated by the Secretary under section 526 of the Federal Food, Drug, and Cosmetic Act (FFDCA).

*Participating drug manufacturer* means a manufacturer that has entered into a Pharmaceutical Pricing Agreement with the Secretary.

*Pharmaceutical Pricing Agreement (PPA)* means an agreement described in section 340B(a)(1) of the PHSA.

*Secretary* means the Secretary of Health and Human Services and any other officer or employee of the Department of Health and Human Services to whom the authority involved has been delegated.

*Section 340B* means section 340B of the PHSA.